Evaluation of CAE on the Mild Cognitive Impairment for the Efficacy and Safety; A 12week, Multi-center, Randomized, Double-blind, Placebo-Controlled Clinical Trial
- Conditions
- Mental and behavioral disorders
- Registration Number
- KCT0002792
- Lead Sponsor
- utraPharmTech
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 100
Subject who have decreased CERAD-K(Consortium to Establish a Registry for Alzheimer’s Disease-Korean version) memory score(-1.0SD<=CERAD-K memory score) comparing to the same age and education group.
1. People who are being hospitalized or within 3 months after hospital discharge for any types of malignant tumors, severe cardiovascular diseases (stroke, hemorrhage, etc), and sever heart diseases (unstable angina, myocardial infarction, heart failure, arrhythmias requiring treatments).
2. People who have major depressive disorders categorized by Diagnostic and Statistical Manual of Mental Disorders-IV
3.People who have poor cognitive function and have Alzheimer’s disease, Parkinson’s disease, or stroke. (The diagnosis of Alzheimer’s disease is based on Diagnostic and Statistical Manual of Mental Disorders-IV)
Study & Design
- Study Type
- Interventional Study
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method ADAS-cog(Alzheimer’s Disease Assessment Scale-Korean version-cognitive subscale) memory
- Secondary Outcome Measures
Name Time Method Adverse Event